Tysabri Resource Center

You can use this section to get information about Tysabri, PML and Avonex from sources such as the FDA. If you feel you have been harmed due to Tysabri use, please contact Weitz & Luxenberg for a free case evaluation. Please
fill out this simple form, call us at 1 (800) 476-6070, or email us at clientrelations@weitzlux.com.

Alert for Healthcare Professionals Natalizumab (marketed as Tysabri)

Biogen-IDEC has suspended marketing of Tysabri and all further dosing of patients in on-going clinical trials. This decision was made after confirmation of one fatal case and one additional case of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri for multiple sclerosis (MS). (more)

FDA Issues Public Health Advisory on Tysabri, a New Drug for MS

The Food and Drug Administration (FDA) today issued a public health advisory to inform patients and health care providers about the suspended marketing of Tysabri (nataluzimab) while the agency and the manufacturer evaluate two serious adverse events reported with its use. (more)

First Monoclonal Antibody Treatment For Multiple Sclerosis Approved

Natalizumab, the new product, is a monoclonal antibody bioengineered from part of a mouse antibody to closely resemble a human antibody. It is being marketed under the tradename Tysabri. The product is given intravenously once a month in a physician's office. (more)

Click To Talk To Us Online

see also:

Links & Numbers Tysabri, PML and Avonex from sources such as the FDA
Tysabri Resource Center-FDA information about Tysabri, PML and Avonex.

Frequently Asked Questions Multiple sclerosis medication Tysabri, Avonex, and PML Q&A
FAQs about the multiple sclerosis medication Tysabri, Avonex, and PML.